Ascletis

Ascletis was founded in 2013 as a research-driven innovative biotechnology company and was listed on the Hong Kong Stock Exchange in 2018 (1672.HK). Ascletis focuses on the research and commercialization of innovative drugs in three major disease areas: viral hepatitis, non-alcoholic steatohepatitis (NASH), and HIV/AIDS, addressing unmet clinical needs of patients both within and outside China.